Video

Dr. Dorff on state of second-line treatment for metastatic urothelial cancer

Author(s):

Urology Times staff

Tanya Dorff, MD, discusses the currently available therapeutic options for patients with metastatic urothelial cancer who have progressed on frontline treatment. Dorff is a medical oncologist, section chief of Genitourinary Disease Program, and associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center.

Related Videos
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
1 expert is featured in this series.
Blurred interior of hospital | Image Credit: © jakkapan - stock.adobe.com
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
1 expert is featured in this series.
Related Content
Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial
January 14th 2025

Bladder tumor-focused adaptive radiotherapy shows feasibility in phase 2 trial

Hannah Clarke
“In this phase 2 study, an image-guided adaptive strategy enabled radiotherapy dose escalation to over 86% of patients’ bladder tumors without significant increase in toxicity,” wrote the authors.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
January 10th 2025

CREST: Sasanlimab hits primary end point of EFS for NMIBC

Benjamin P. Saylor
Results from CREST will be presented at an upcoming medical conference.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021

Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app

Urology Times staff
“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
9MW2821/toripalimab awarded breakthrough therapy designation in China for mUC
January 9th 2025

9MW2821/toripalimab awarded breakthrough therapy designation in China for mUC

Hannah Clarke
9MW2821 was previously awarded a breakthrough therapy designation as a monotherapy for locally advanced or metastatic urothelial carcinoma.
Disitamab vedotin/toripalimab shows encouraging efficacy in urothelial carcinoma
January 8th 2025

Disitamab vedotin/toripalimab shows encouraging efficacy in urothelial carcinoma

Hannah Clarke
At a median follow-up of 33.2 months, the confirmed objective response rate was 73.2%.
© 2025 MJH Life Sciences

All rights reserved.